share_log

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K：外國發行人報告（業績相關）
美股sec公告 ·  06/27 02:14
牛牛AI助理已提取核心訊息
Cybin Inc., a clinical-stage biopharmaceutical company, announced its fiscal year 2024 financial results and recent business highlights. The company reported significant progress with its two lead programs, CYB003 and CYB004, aimed at treating Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), respectively. CYB003 received FDA Breakthrough Therapy Designation and is expected to enter Phase 3 trials in summer 2024. CYB004 has initiated a Phase 2 study. Cybin ended the fiscal year with C$209 million in cash and completed a U.S.$150 million oversubscribed private placement. The company's net loss increased year-over-year, with C$78 million reported for the fiscal year ended March 31, 2024. Cybin's CEO, Doug Drysdale, expressed optimism about the company's direction and the potential impact of its programs on mental health treatment. The company also strengthened its intellectual property portfolio with over 60 granted patents and more than 200 pending applications.
Cybin Inc., a clinical-stage biopharmaceutical company, announced its fiscal year 2024 financial results and recent business highlights. The company reported significant progress with its two lead programs, CYB003 and CYB004, aimed at treating Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), respectively. CYB003 received FDA Breakthrough Therapy Designation and is expected to enter Phase 3 trials in summer 2024. CYB004 has initiated a Phase 2 study. Cybin ended the fiscal year with C$209 million in cash and completed a U.S.$150 million oversubscribed private placement. The company's net loss increased year-over-year, with C$78 million reported for the fiscal year ended March 31, 2024. Cybin's CEO, Doug Drysdale, expressed optimism about the company's direction and the potential impact of its programs on mental health treatment. The company also strengthened its intellectual property portfolio with over 60 granted patents and more than 200 pending applications.
臨床階段生物製藥公司Cybin Inc.宣佈其2024財年財務業績和最新業務亮點。該公司在旨在治療重度抑鬱症（MDD）和廣泛性焦慮障礙（GAD）的兩項主要項目CYB003和CYB004方面取得了顯著進展。CYB003已獲得FDA突破性治療認證，預計將於2024年夏季進入第三階段試驗。CYB004已着手進行第二階段研究。Cybin以2.09億加元現金結束了財年，並完成了1.5億美元超額認購的定向增發。公司淨虧損同比增加，截至2024年3月31日財年報告的淨虧損爲7,800萬加元。Cybin的CEO Doug Drysdale對公司的發展方向和其項目對精神健康治療的潛在影響表示樂觀。公司還通過獲得超過60項專利和200多項待批申請，加強了其知識產權組合。
臨床階段生物製藥公司Cybin Inc.宣佈其2024財年財務業績和最新業務亮點。該公司在旨在治療重度抑鬱症（MDD）和廣泛性焦慮障礙（GAD）的兩項主要項目CYB003和CYB004方面取得了顯著進展。CYB003已獲得FDA突破性治療認證，預計將於2024年夏季進入第三階段試驗。CYB004已着手進行第二階段研究。Cybin以2.09億加元現金結束了財年，並完成了1.5億美元超額認購的定向增發。公司淨虧損同比增加，截至2024年3月31日財年報告的淨虧損爲7,800萬加元。Cybin的CEO Doug Drysdale對公司的發展方向和其項目對精神健康治療的潛在影響表示樂觀。公司還通過獲得超過60項專利和200多項待批申請，加強了其知識產權組合。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。